Applied Genetic Technologies Corp., backed by technology from the University of Florida, raises $37.5m in a record area venture round.
Applied Genetic Technologies Corp. (AGTC), a US-based biotechnology company that receives much of its technology licenced from the University of Florida, has raised a $37.5m series B round.
GlaxoSmithKline’s venture unit SR One led the round along with life science venture firm Alta Partners. They were joined by new investor Osage University Partners, a venture fund that invests in university start-ups. Also joining the round were existing venture firm investors Intersouth Partners, InterWest, and MedImmune Ventures.
Intersouth, InterWest, and MedImmune…
